A researcher from Tel Aviv University has developed a way to produce dairy products from yeast. Professor Tamir Tuller from the university’s Department of Biomedical Engineering is the researcher behind this innovative development. Tuller worked together with Dr. Eyal Iffergan, a food technology entrepreneur, to set up Imagindairy, a start-up company that plans to make cow’s milk using yeast.
This development comes at a time when researchers are working on finding substitutes for milk because dairy farming damages not only the environment but also human health.
Tuller explained that Imagindairy’s objective was to create milk that contained all the nutritional contents of cow’s milk along with a similar texture, aroma and taste. The only things excluded from the equation would be the damage caused to the environment during dairy farming and the suffering that cows go through during the dairy process.
These parameters will make Imagindairy’s cheese and milk products healthier than milk that is obtained from animals because the products will not contain somatic cells, lactose and cholesterol.
In his report, Tuller explained that the start-up also includes food experts and Strauss Company food engineers. For now, the researchers are working on leveraging the milk proteins from yeast to produce cheese using those proteins. Tuller explained that this was a long process of improvement, especially considering that the product is not similar to substitutes, such as nut milks (soy or almond milk, for example).
Tuller added that the company plans to manufacture dairy products through the introduction of yeast genomes, resulting in products similar to those derived from animals. Tuller and his lab have spent more than a decade exploring and specializing in the engineering and modeling of gene expression through the use of machine learning, computational modeling of molecular evolution and biophysical simulations. The models are then used to facilitate the manufacture of heterologous proteins more efficiently, which in turn makes them cheaper.
Tuller explained that the genome of each living creature is comprised of genes that contain an encoded formula for making amino acid chains which manufacture proteins. However, the genome also has information that ciphers gene expression. He explained that this was a complicated process involving protein creation.
Imagindairy has been working with Tel Aviv University’s technology transfer company, Ramot, in its efforts. Ramot CEO Keren Primor Cohen states that Tuller’s groundbreaking technology could revolutionize the dairy industry.
The study findings were reported in the “News Medical and Life Sciences” journal.
Aside from researching how to generate milk from yeast, another biotech company, CNS Pharmaceuticals Inc. (NASDAQ: CNSP), has placed its focus on finding solutions to the worldwide challenge of brain tumors. The company already has a drug candidate (Berubicin) undergoing clinical trials, which is giving patients with brain tumors hope that a treatment could soon be available.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. The movement toward…
Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as…
Immunotherapy is a relatively new approach in the treatment of cancer and it has had…
PLA gives overlooked biological evidence its own analysis before combining the findings. Published HCC research…
Abdul El-Sayed, a Democrat vying to win a U.S. Senate seat in Michigan, has become…
Many people have been taken by surprise as the flu season gets underway a lot…